OncoSec Medical Incorporated (ONCS) financial statements (2020 and earlier)

Company profile

Business Address 24 N. MAIN STREET
PENNINGTON, NJ 08534
State of Incorp. NV
Fiscal Year End July 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9254112932
Cash and cash equivalents9254112932
Prepaid expense  2112
Other current assets    00
Other undisclosed current assets3323   
Total current assets:122929132934
Noncurrent Assets
Operating lease, right-of-use asset6 
Property, plant and equipment111232
Other noncurrent assets000000
Total noncurrent assets:812332
TOTAL ASSETS:203030153236
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:945310
Accrued liabilities011210
Employee-related liabilities0  000
Other undisclosed accounts payable and accrued liabilities9442  
Debt10    
Other undisclosed current liabilities01103 
Total current liabilities:1056330
Noncurrent Liabilities
Long-term debt and lease obligation6     
Operating lease, liability6 
Liabilities, other than long-term debt 1111 
Other liabilities 1111 
Total noncurrent liabilities:61111 
Other undisclosed liabilities     3
Total liabilities:1767543
Stockholders' equity
Stockholders' equity attributable to parent32423112833
Common stock000000
Additional paid in capital185178146948872
Accumulated other comprehensive income (loss)00(0)(0)  
Accumulated deficit(188)(164)(134)(95)(73)(47)
Warrants and rights outstanding6111112138
Total stockholders' equity:32423112833
TOTAL LIABILITIES AND EQUITY:203030153236

Income statement (P&L) ($ in millions)

1/31/2020
TTM
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Operating expenses(38)(30)(36)(21)(27)(21)
Other undisclosed operating income     0
Operating loss:(38)(30)(36)(21)(27)(21)
Nonoperating income000   
Foreign currency transaction loss, before tax(0)(0)    
Interest and debt expense(0)(0)    
Loss from continuing operations before equity method investments, income taxes:(38)(30)(36)(21)(27)(21)
Other undisclosed loss from continuing operations before income taxes(0)(0)(3)   
Loss from continuing operations before income taxes:(38)(30)(39)(21)(27)(21)
Income tax expense (benefit)0(0)(0)(0)(0)(0)
Net loss attributable to parent:(38)(30)(39)(21)(27)(21)
Other undisclosed net income (loss) available to common stockholders, basic268 (95)   
Net income (loss) available to common stockholders, diluted:230(30)(134)(21)(27)(21)

Comprehensive Income ($ in millions)

1/31/2020
TTM
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Net loss:(38)(30)(39)(21)(27)(21)
Other comprehensive income003921  
Comprehensive income (loss):(38)(30)00(27)(21)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (39)   
Comprehensive income (loss), net of tax, attributable to parent:(38)(30)(39)0(27)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: